Secondary endpoints.
SKIN, SECONDARY
A key secondary endpoint included the change in the severity of clinical reactions during OFC, as assessed by using a modified PRACTALL scale to score symptoms (Skin puncture testing to peanut extract was included as a secondary endpoint and surrogate marker of mast cell reactivity in vivo. All patients had a positive skin puncture test to undiluted peanut extract at baseline, with a median wheal area of 126 mmAn additional secondary endpoint was the percentage of basophils activated ex vivo by peanut extract. All patients had a positive basophil activation test at baseline to at least 1 dilution of peanut extract (mean peak response to peanut, 31.7%; range, 3.5–70.7; 